Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2011

GlobalData
February 20, 2012
90 Pages - SKU: GBDT6827898
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2011

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q4 2011. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and primary and secondary research.

Scope
  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the last five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.


Additional Information

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q4 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions registered in the pharmaceutical and healthcare industry in Q4 2011. The report presents detailed comparative data on the number of deals and their value in the past five quarters subdivided into deal types, segments, and geographies. The report also offers information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database and through primary and secondary research.

Deal Values Of Mergers & Acquisitions Decline 39% In Q4 2011

Mergers and acquisitions (M&As), including asset transactions, reported a decline of 39% in deal values in Q4 2011, with pharmaceutical companies reducing their investments due to apprehensions about macro-economic conditions and patent expiries. The industry recorded $25.9 billion in Q4 2011, as compared to $42.1 billion in Q3 2011. On a year-on-year basis, deal values declined in Q4 2011, when compared to $47.1 billion in Q4 2010. However, the number of deals reported an increase in Q4 2011 with 231 deals as compared to 222 deals in Q3 2011. On a year-on-year basis, the number of deals recorded a decrease in Q4 2011, when compared to 303 deals in Q4 2010.

The central nervous system therapeutics market accounted for the majority of M&As during Q4 2011. The market recorded 22 deals worth $2.8 billion in Q4 2011. Infectious Disease therapeutics market was in second place with 20 deals worth $12.5 billion.

Gilead Sciences’ $11.2 billion acquisition of Pharmasset, a clinical-stage pharmaceutical company, to advance its efforts to develop an all-oral regimen for the treatment of chronic hepatitis C virus (HCV) and leverage its infrastructure and expertise in antiviral drug development, manufacture and commercialization, was one of the high-value transaction in Q4 2011.

According to Khaleeq Zakariya, Analyst at GlobalData, “The global M&A deal values have declined in 2011. This trend was primarily driven by continued Eurozone crisis and other macroeconomic factors in the US. Across the globe, the North America region witnessed highest number of high-value transactions in Q4 2011”.

Partnership Deals Decrease 11% In Q4 2011

Partnerships in the pharmaceutical and healthcare industry reported a decrease in the number of deals in Q4 2011. The industry reported 171 deals in Q4 2011, as compared to 193 deals in Q3 2011. However, deal values increased from $4.1 billion in Q3 2011 to $5.1 billion in Q4 2011. On a year-on-year basis, the number of deals decreased and deal values increased in Q4 2011, when compared to 256 deals worth $4.2 billion in Q4 2010. Out of 171 deals reported in Q4 2011, 117 were co-development deals, 12 were co-marketing deals, 29 were joint venture deals and 13 were related to other category

The oncology therapeutics market stood ahead of all other therapeutics markets with 31 deals worth $875.6m in Q4 2011, the central nervous system therapeutics market followed with 21 deals worth $2.1 billion.

Total Value Of Licensing Agreements Increase In Q4 2011

The total value of licensing agreements in the pharmaceutical and healthcare industry reported an increase with companies in the industry increasing their investments to buy patents. The industry recorded deals worth $4.3 billion in Q4 2011, as compared to $1.5 billion in Q3 2011. Besides, the number of deals decreased to 110 in Q4 2011 from 129 in Q3 2011. On a year-on-year basis, licensing activity decreased in Q4 2011, when compared with 193 deals worth $9.9 billion in Q4 2010. Licensing agreements recorded an increase in the receipt of upfront payments and milestone payments in Q4 2011. The segment reported $1.2 billion and $2.8 billion in upfront payment and milestone payments in Q4 2011, as compared to $199.6m and $1.1 billion respectively in Q3 2011.

Some of the key licensing deals in Q4 2011 include Biogen’s licensing agreement with Portola Pharmaceuticals worth $553.5m to develop and commercialize novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases; Roche’s licensing agreement with PTC Therapeutics, worth $490m for PTC's Spinal Muscular Atrophy (SMA) programme and MacroGenics and Les Laboratoires entering into option for a license agreement for the development and commercialization of MGA271, a proprietary product candidate of MacroGenics.

According to Khaleeq Zakariya, Analyst at GlobalData, “The licensing agreements in pharmaceutical and healthcare industry are a tool to improve manufacturing facility, distribution channels, to provide platform for entering in new markets and a wide scope for the commercialization of the products and technologies. During Q4 2010 to Q4 2011, the oncology therapeutics market recorded the highest number of licensing agreements followed by Infectious disease therapeutics market”.

Pharmaceutical And Healthcare Companies Were Sucessful In Raising Funds From Venture Capital Investors In Q4 2011

Companies in the pharmaceutical and healthcare industry were successful in raising funds from venture capital (VC) investors in Q4 2011. The industry recorded 216 deals worth $1.8 billion in Q4 2011, as compared to 169 deals worth $1.6 billion in Q3 2011. Out of 216 deals recorded in Q4 2011, 116 were start-up stage financing deals worth $870.3m, 61 were growth/ expansion stage financing deals worth $624.1m, 17 were later stage financing deals worth $296.7m and 22 seed stage financing deals worth $17.1m

The oncology therapeutics market remains lucrative for the venture capital investors. The market managed to raise $510.6m in Q4 2011 and stood ahead of all therapeutics markets. In second place was immunology therapeutics market with $409.7m.

According to Khaleeq Zakariya, Analyst at GlobalData, “The pharmaceutical and healthcare industry has witnessed increasing trend of venture capital deals in past four quarters of 2011. The increase in deals number was primarily driven by high medical unmet need and potential drug therapies in developmental pipeline. Across the Globe, North America region witnessed maximum number of high-value transaction in Q4 2011. Oncology and central nervous system therapeutics market remains an area of interest for the venture capitalists. As these, segments have high medical unmet need and high return on investments”.

Deal Activity In North America Surge In Q4 2011

Deal activity in North America surge upward with slight improvement in economic conditions in Q4 2011. The region registered 672 deals worth $62.2 billion in Q4 2011, as compared to 566 deals worth $56.3 billion in Q3 2011. On a year-on-year basis, the number of deals and the deal values decreased in Q4 2011, when compared to 779 deals worth $63.1 billion in Q4 2010. The region was suscessful in recording some 14 major transactions which crossed the $1 billion mark in Q4 2011.

Europe recorded a decrease in the number of deals and an increase in deal values in Q4 2011 with 220 deals worth $10.9 billion, as compared to 248 deals worth $8.8 billion in Q3 2011. On a year-on-year basis, the number of deals and the deal values decreased in Q4 2011, when compared to 368 deals worth $31.8 billion in Q4 2010.

Asia Pacific recorded an increase in deal values in Q4 2011. The region reported deals worth $11.4 billion in Q4 2011, as compared to $6.2 billion in Q3 2011. However, the number of deals declined to 204 in Q4 2011 from 240 in Q3 2011.

More Manufacturing, Packaging & Detailing reports by GlobalData

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab Emirates by GlobalData
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - United Arab EmiratesSummaryGlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ...
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Philippines by GlobalData
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - PhilippinesSummaryGlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Philippines”. ...
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Indonesia by GlobalData
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - IndonesiaSummaryGlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Indonesia”. ...
Triptans (Migraine) - Forecast and Market Analysis to 2023 by GlobalData
Triptans (Migraine) - Forecast and Market Analysis to 2023SummaryThe migraine market is saturated with generic drugs, and the remaining branded products already on the market ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 1,500  
    Global Site License  USD 4,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!